Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Heather, Jacene"'
Autor:
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schöder, Heather Jacene
Publikováno v:
HemaSphere, Vol 7, Iss 2, p e826 (2023)
While most patients with follicular lymphoma (FL) have excellent outcomes with frontline chemoimmunotherapy (CIT), a subset of patients will experience early progression, which is associated with poor subsequent outcomes. Novel biomarkers are needed
Externí odkaz:
https://doaj.org/article/83d25c36f6aa4d008cd0ecfabeefe63a
Publikováno v:
Expert Review of Anticancer Therapy. 22:1163-1175
Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate thatThis review discusses the development and studies leading to the approval of
Autor:
Maha Hussain, Michael A. Carducci, Noel Clarke, Sarah E. Fenton, Karim Fizazi, Silke Gillessen, Heather Jacene, Michael J. Morris, Fred Saad, Oliver Sartor, Mary-Ellen Taplin, Neha Vapiwala, Scott Williams, Christopher Sweeney
Publikováno v:
Journal of Clinical Oncology. 40:3011-3014
Autor:
Kimberly Perez, Heather Jacene, Jason L Hornick, Chao Ma, Nuno Vaz, Lauren K Brais, Holly Alexander, William Baddoo, Kristina Astone, Edward D Esplin, John Garcia, Daniel M Halperin, Matthew H Kulke, Jennifer A Chan
Publikováno v:
Endocrine-Related Cancer. 29:533-544
Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options are limited. Approximately 27% carry pathogenic germline succinate dehydrogenase (SDHx) mutations; the
Autor:
Thomas Hope, Samuel Mehr, Michael Morris, Daneng Li, MD Daniel Halperin, Jonathan Strosberg, Heloisa Soares, Heather Jacene, Marianne Pavel, Kunz Pamela L., Denis Ferreira, Joanne Li, Kimberly Ma, Jessica Rearden, Susan Moran, Simron Singh
Publikováno v:
Endocrine Abstracts.
Autor:
Reid W Merryman, Robert A Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M McHugh, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Eric D. Jacobsen, Caron A. Jacobson, Austin I Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O Odejide, Erin M. Parry, Heather Jacene, Hyesun Park, Parastoo B. Dahi, Yago Nieto, Robin Joyce, Yi-Bin Chen, Margaret A. Shipp, Alex F. Herrera, Philippe Armand
Publikováno v:
Blood Advances.
Improved biomarkers are needed to guide the optimal use of autologous stem cell transplantation (ASCT) for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified u
Autor:
Praful Ravi, Bridget Whelpley, Emma Kelly, Andrew Wolanski, Jolivette Ritzer, Matthew Robertson, Hina Shah, Alicia K. Morgans, Xiao X. Wei, Rajitha Sunkara, Mark Pomerantz, Mary-Ellen Taplin, Kerry L. Kilbridge, Atish D. Choudhury, Heather Jacene
Publikováno v:
Journal of Nuclear Medicine. 64:349-350
Autor:
Aman Chauhan, Susanne Arnold, Jill Kolesar, William Carson, Heidi Weiss, Rani Jayswal, Donglin Yan, Riham El Khouli, Aman Khurana, Jan Beumer, Heloisa Soares, Mary Mulcahy, Thorvardur Halfdanarson, Daneng Li, Heather Jacene, Percy Ivy, Elise Kohn, John Wright, Larry Rubinstein, Zeta Chow, Piotr Rychahou, Mark B. Evers, Charles Kunos, Lowell Anthony, Bhavana Konda
Publikováno v:
Cancer Research. 83:CT194-CT194
Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitizat
Autor:
Praful Ravi, Emma Kelly, Bridget Whelpley, Atish Dipankar Choudhury, Rajitha Sunkara, Mark Pomerantz, Mary-Ellen Taplin, Kerry L. Kilbridge, Xiao X. Wei, Alicia K. Morgans, Renata Rocha de Almeida Bizzo, Andrew Wolanski, Heather Jacene
Publikováno v:
Journal of Clinical Oncology. 41:108-108
108 Background: LuPSMA received FDA approval in March 2022 for patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). Clinical implementation of this treatment requires multidisciplinary team (MDT) involvement and has been
Publikováno v:
Journal of Nuclear Medicine Technology. 50:213-214